Auriga Partners

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Patrowl is a cybersecurity platform designed to enhance the management of external security posture through automated detection and remediation of vulnerabilities. Developed by cybersecurity experts, Patrowl utilizes artificial intelligence to conduct continuous penetration tests, enabling real-time identification of both known and shadow IT assets and their associated vulnerabilities. The platform provides a comprehensive overview of an organization's security status, along with tailored solutions that can be easily accessed and implemented via a user-friendly dashboard. Clients can monitor remediation efforts and verify the effectiveness of fixes with a single click. By streamlining cybersecurity processes, Patrowl aims to empower organizations to elevate their security levels and diminish the threat posed by cybercriminals.

Vade Secure is a leader in cybersecurity specializing in anti-phishing, spear phishing, malware, and ransomware protection through advanced heuristic filtering. The company's technology analyzes incoming emails, including links, attachments, and content, to identify and neutralize threats, even zero-day attacks and highly targeted scams. Vade Secure also addresses the issue of low-priority emails through its Graymail Management feature, which automatically sorts ads, social media notifications, and newsletters into a separate folder while providing a Safe Unsubscribe option to eliminate them permanently. With over 500 million mailboxes protected in 76 countries, Vade Secure's solutions are trusted by major ISPs, OEMs, and enterprises globally. The company operates in five countries—USA, Canada, France, Hong Kong, and Japan—and provides round-the-clock support to its clients.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Flash Therapeutics is a biotechnology company based in Labège, France, specializing in gene and cell-based therapies through its proprietary lentiviral platform. Established in 2005 and formerly known as Vectalys SAS, the company focuses on developing advanced viral vector technologies to transduce difficult-to-transfect cells, including primary cells and stem cells. Flash Therapeutics offers a range of services, including gene silencing, gene over-expression, cell-based assay development, and protein expression. It also conducts preclinical trials for gene therapy and produces concentrated viral vectors for research purposes. The company is committed to creating innovative solutions for drug screening and the development of cellular and animal models to validate candidate genes.

EnobraQ, founded in 2015 as a start-up emerging from a pre-competitive research initiative supported by Toulouse White Biotechnology, focuses on innovative technologies that utilize CO2 as a feedstock for industrial fermentation. The company's efforts are driven by ecological and economic considerations, targeting a diverse array of markets including nutrition, agri-food, cosmetics, pharmacology, and bioplastics. By developing breakthrough methods to transform CO2 into valuable products, EnobraQ aims to contribute to sustainable practices across various industries.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

VitaDX is a startup focused on enhancing cancer diagnosis through the application of artificial intelligence and fluorescence imaging technology. Its primary product, VisioCyt®, is designed for the early detection of bladder cancer, utilizing a simple urine sample to improve upon the traditional urinary cytology methods. By integrating machine learning with advanced imaging techniques, VitaDX aims to identify potential abnormalities in the urinary excretory tract. This innovative approach enables healthcare providers to offer more accurate and timely cancer diagnostic services, ultimately leading to improved treatment options and better patient outcomes.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

One More Company, Inc. is a U.S.-based corporation specializing in contextual intelligence email services, with a focus on enhancing the email experience for users. Its flagship product, Senders™, acts like Caller ID for email, providing recipients with essential information about the sender directly within the email, regardless of the platform or device used. Senders™ is a patent-pending service that prioritizes user privacy and security, adhering to a digital ethics framework centered on consumer control and transparency. The company, founded by experienced executives from notable tech firms, aims to filter valuable messaging from irrelevant noise, offering simple and intuitive solutions for individuals and businesses. One More Company does not rely on advertising revenue or data selling, placing the interests of its users at the forefront of its mission. With offices in New York and Paris, One More Company is dedicated to creating a positive consumer experience through thoughtful product design that incorporates privacy and security from the outset.

Nexthink S.A. is a company specializing in end-user experience management, providing a real-time analytics platform designed to enhance business productivity by converting endpoint analytics and employee feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, Nexthink serves Global 5000 organizations across various sectors, including education, finance, healthcare, and manufacturing, with a focus on improving the digital workplace experience. Its offerings include incident and problem management solutions, change management tools, and a Digital Experience Score system that integrates quantitative data with user feedback. By utilizing machine learning and automation, Nexthink enables IT teams to detect, diagnose, and remediate issues efficiently across all endpoints, ultimately enhancing employee experience and operational efficiency. The company operates globally, with a presence in the United States, Europe, the Middle East, and Asia Pacific.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Theranexus is a clinical-stage biopharmaceutical company based in France, focused on developing innovative drug candidates for central nervous system (CNS) disorders. The company aims to address significant medical needs in brain disorders by creating combinations of two distinct drugs: one targeting neuronal activity and the other focusing on glial cells. Its key drug candidates include THN102, designed to treat excessive daytime sleepiness in Parkinson's disease; THN201, aimed at addressing neurocognitive disorders associated with Alzheimer's disease; and THN101, which targets neuropathic pain. Through its unique therapeutics platform, Theranexus seeks to enhance treatment efficacy for various CNS conditions.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Amoeba is a France-based company dedicated to the development, production, and commercialization of green biocide water treatment chemicals for the industrial sector. Its primary product, BIOMEBA, utilizes the biocidal properties of Willaertia magna to effectively address bacterial risks in cooling towers. By focusing on environmentally friendly solutions, Amoeba aims to provide sustainable alternatives in water treatment, enhancing safety and efficiency in industrial applications.

Nexthink S.A. is a company specializing in end-user experience management, providing a real-time analytics platform designed to enhance business productivity by converting endpoint analytics and employee feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, Nexthink serves Global 5000 organizations across various sectors, including education, finance, healthcare, and manufacturing, with a focus on improving the digital workplace experience. Its offerings include incident and problem management solutions, change management tools, and a Digital Experience Score system that integrates quantitative data with user feedback. By utilizing machine learning and automation, Nexthink enables IT teams to detect, diagnose, and remediate issues efficiently across all endpoints, ultimately enhancing employee experience and operational efficiency. The company operates globally, with a presence in the United States, Europe, the Middle East, and Asia Pacific.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

eXo Platform SAS is a provider of Java middleware and open-source digital collaboration software based in Paris, France, with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company offers a range of solutions designed to facilitate collaboration and knowledge sharing within organizations. Its flagship product, eXo Platform, allows users to build enterprise social networks, websites, and social intranets, while other offerings include eXo Portal for centralized access to content, eXo Wallet for digital transactions, and various tools for document and content management. eXo's software also supports workflow design, project collaboration, and knowledge capital organization. Serving a diverse clientele across sectors such as government, financial services, and telecommunications, eXo has established strategic partnerships with notable companies like Red Hat, Capgemini, and Atos Origin to enhance its market presence.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Firalis is a biotechnology company specializing in the discovery, development, and regulatory qualification of novel biomarkers aimed at enhancing diagnostics for various diseases. The company focuses on biomarkers related to inflammatory disorders, including common conditions like atherosclerosis and rheumatoid arthritis, as well as rare diseases such as systemic or autoimmune vasculitis. Firalis is particularly invested in addressing drug-induced organ injuries in major targets like the kidneys, liver, and vasculature. By leveraging a unique network of clinical centers of excellence, Firalis conducts biomarker qualification studies to ensure high success potential for its diagnostic kits. The company is headquartered in Huningue, France, strategically located in BioValley, which is known for its proximity to significant pharmaceutical hubs in Europe. Through its innovative biomarker services, Firalis aims to improve patient outcomes, enhance therapeutic decisions, and reduce overall healthcare costs.

Miliboo is a furniture brand that designs and offers a wide array of contemporary furniture products, including sofas, armchairs, bar stools, office chairs, tables, storage solutions, and garden furniture. Founded in 2005, the company is based in Pringy, France. Miliboo's product portfolio also features furniture for children and decorative items such as table lamps. The company is committed to providing stylish and functional furniture for various settings, catering to both residential and commercial needs.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Codenvy offers a cloud development platform that facilitates coding, building, and testing applications. By moving the local desktop workspace—comprising the editor, builder, and tester runtimes—into the cloud, Codenvy allows enterprises to access on-demand workspaces that promote collaboration and eliminate physical constraints. This innovative approach enhances the development process by providing a flexible and efficient environment tailored for modern software development needs.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Eptica S.A. is a company based in Boulogne-Billancourt, France, specializing in customer relationship management (CRM) software aimed at business-to-business (B2B) marketplaces. Established in 2001, Eptica develops solutions that enhance real-time interactions between enterprises and their clients, suppliers, and partners through various digital channels. Its offerings include multi-channel communications, self-service options, and tools for email management and knowledge sharing. Eptica also provides consulting, technical support, and training services to clients across sectors such as banking, insurance, retail, tourism, and public institutions. By integrating artificial intelligence, Eptica aims to transform digital relationships into meaningful exchanges, ultimately improving customer engagement and operational efficiency. The company operates as a subsidiary of Enghouse Systems Limited.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Neolane, Inc. is a provider of conversational marketing technology that specializes in marketing automation and cross-channel campaign management software for both business-to-business and business-to-consumer marketers. The company enables organizations to create and maintain one-to-one lifetime dialogues with their customers, enhancing revenue generation and marketing efficiency. Neolane has demonstrated significant growth, recording $58 million in revenue in 2012, which represented a 40% increase from the previous year. The company has received recognition for its innovative approach, being named #64 on Forbes' list of America's Most Promising Companies in 2013. Neolane's technology is utilized by over 400 leading global companies, including Alcatel Lucent, Barnes & Noble, Orange, Sears Canada, Sephora Europe, and Sony Music, helping them navigate customer engagement challenges effectively.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Isocell SA is a biotechnology company based in Paris, France, specializing in the development and manufacture of nutritional supplements. The company offers a range of products designed to support health and well-being, including GliSODine VITALITE for energy recovery, GliSODin COMPLEX, which protects the activity of SuperOxide Dismutase in intestinal cells, and GliSODine, an antioxidant that combats oxidative stress related to aging. Additionally, Isocell provides GliSODine DEFENSES to enhance immune function, GliSODine DRAINANTE to aid digestion and detoxification, and GliSODine MOISTURIZING for skin health. Other offerings include GliSODine SOLAIRE, which prepares the skin for sun exposure, and GliSODine DETOXIFIANTE for overall purification and revitalization. Founded in 2001, Isocell serves customers in France and internationally, including markets in the United States, Japan, and Europe. The company also has a professional line of nutricosmetics known as GliSODin Skin Nutrients, launched in 2008, which focuses on providing essential nutrients to protect the skin from oxidative stress.

Founded in 2001, Availpro is a prominent provider of e-booking software solutions designed to enhance hotel occupancy and revenue while reducing costs. The company offers a fully integrated online distribution system that enables hotel owners to manage all aspects of their operations, from hotel management to distribution channels. Availpro equips managers with innovative tools to optimize pricing, maximize commission-free bookings through official websites, and streamline decision-making processes. The company has developed extensive expertise in creating connectivity solutions that link various software platforms, partnering with over 300 companies worldwide, including major online travel agencies and global distribution systems. This commitment to simplifying the distribution process and enhancing efficiency positions Availpro as a reliable and high-performance tool for the hospitality industry. With a dedicated international team of 75 professionals, Availpro continues to focus on delivering effective solutions for its clients.

CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.

Miliboo is a furniture brand that designs and offers a wide array of contemporary furniture products, including sofas, armchairs, bar stools, office chairs, tables, storage solutions, and garden furniture. Founded in 2005, the company is based in Pringy, France. Miliboo's product portfolio also features furniture for children and decorative items such as table lamps. The company is committed to providing stylish and functional furniture for various settings, catering to both residential and commercial needs.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Eve.com specializes in massively multiplayer online roleplaying games (MMORPGs), boasting a diverse portfolio that includes popular titles such as Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe. The company focuses on creating immersive gaming experiences that engage players in expansive virtual worlds, fostering community interaction and collaboration. Through its innovative approach to game design and storytelling, Eve.com has established a strong presence in the gaming industry, appealing to a dedicated audience of gamers.

Nexthink S.A. is a company specializing in end-user experience management, providing a real-time analytics platform designed to enhance business productivity by converting endpoint analytics and employee feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, Nexthink serves Global 5000 organizations across various sectors, including education, finance, healthcare, and manufacturing, with a focus on improving the digital workplace experience. Its offerings include incident and problem management solutions, change management tools, and a Digital Experience Score system that integrates quantitative data with user feedback. By utilizing machine learning and automation, Nexthink enables IT teams to detect, diagnose, and remediate issues efficiently across all endpoints, ultimately enhancing employee experience and operational efficiency. The company operates globally, with a presence in the United States, Europe, the Middle East, and Asia Pacific.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

eXo Platform SAS is a provider of Java middleware and open-source digital collaboration software based in Paris, France, with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company offers a range of solutions designed to facilitate collaboration and knowledge sharing within organizations. Its flagship product, eXo Platform, allows users to build enterprise social networks, websites, and social intranets, while other offerings include eXo Portal for centralized access to content, eXo Wallet for digital transactions, and various tools for document and content management. eXo's software also supports workflow design, project collaboration, and knowledge capital organization. Serving a diverse clientele across sectors such as government, financial services, and telecommunications, eXo has established strategic partnerships with notable companies like Red Hat, Capgemini, and Atos Origin to enhance its market presence.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Bag Tech specializes in the development, design, and manufacturing of a diverse range of bags and backpacks. The company produces practical and durable products at wholesale prices, utilizing a facility in Sialkot, Pakistan, which spans over 10,000 square feet. Skilled craftsmen employ modern technology to ensure meticulous care in the manufacturing process. Bag Tech's product lineup includes various types of bags such as kit bags, travel kits, sports kits (including cricket, hockey, boxing, and karate), gym bags, school bags, backpacks, and specialized bags for helmets, shoes, and laptops. Additionally, the company offers protective covers for sports equipment and a selection of ladies' bags, catering to a wide array of customer needs.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

StreamCore is a prominent provider of visibility and performance control solutions designed for managing interactive applications and real-time communications, such as VoIP and video, over wide area networks (WAN) and local area networks (LAN). The company's products offer enterprises comprehensive visibility across network performance, applications, and communication channels, all accessible from a single centralized management console. StreamCore's solutions uniquely integrate visibility with advanced performance control, allowing for efficient monitoring and reporting. This integration enhances the management of application delivery and ensures rapid deployment while maintaining cost-effectiveness for organizations.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.